Several inherited predisposition to cancer syndromes are associated with the development of nervous system tumors. Tuberous sclerosis complex (TSC) is an autosomal dominant disorder in which aected individuals are at risk for developing astrocytomas. One of the genes responsible for this disorder is TSC2, located on chromosome 16p, and encoding a 180 kDa protein (tuberin) that functions in part as a negative regulator of rap1. Previous studies from our laboratory demonstrated that 30% of sporadic astrocytomas have reduced or absent tuberin expression. In addition to loss of tuberin in sporadic astrocytomas, aberrant rap1 mediated signaling may also result from overexpression of rap1. In this study, we test the hypothesis that alterations in the rap1 signaling pathway are frequently observed in certain subsets of gliomas compared to other tumors of the nervous system. Analysis of sporadic astrocytomas and ependymomas demonstrated either increased rap1 or reduced/absent tuberin protein expression in 50 ± 60% of dierent cohorts of these gliomas, compared to 30 ± 33% of sporadic schwannomas and meningiomas and none of eight oligodendrocyte tumors. These results suggest that alterations in the rap1 signaling pathway are important in the development of certain sporadic human gliomas.
Several inherited predisposition to cancer syndromes are associated with the development of nervous system tumors. Tuberous sclerosis complex (TSC) is an autosomal dominant disorder in which aected individuals are at risk for developing astrocytomas. One of the genes responsible for this disorder is TSC2, located on chromosome 16p, and encoding a 180 kDa protein (tuberin) that functions in part as a negative regulator of rap1. Previous studies from our laboratory demonstrated that 30% of sporadic astrocytomas have reduced or absent tuberin expression. In addition to loss of tuberin in sporadic astrocytomas, aberrant rap1 mediated signaling may also result from overexpression of rap1. In this study, we test the hypothesis that alterations in the rap1 signaling pathway are frequently observed in certain subsets of gliomas compared to other tumors of the nervous system. Analysis of sporadic astrocytomas and ependymomas demonstrated either increased rap1 or reduced/absent tuberin protein expression in 50 ± 60% of dierent cohorts of these gliomas, compared to 30 ± 33% of sporadic schwannomas and meningiomas and none of eight oligodendrocyte tumors. These results suggest that alterations in the rap1 signaling pathway are important in the development of certain sporadic human gliomas.
Keywords: astrocytomas; tumor suppressor gene; tuberous sclerosis complex 2; tuberin Studies on the molecular genetic events associated with the development of human malignant astrocytic tumors (the most common subtype of glioma and primary human brain cancer) have demonstrated alterations in the p21-ras signaling pathway. Ampli®cation of the epidermal growth factor receptor (EGF-R) has been detected in a high proportion of the most malignant astrocytoma or glioblastoma multiforme (GBM; Olson et al., 1995) , contributing to increased activation of p21-ras. Previously, we demonstrated elevated levels of p21-ras activity in astrocytoma cell lines as well as fresh GBM surgical specimens Guha et al., manuscript submitted) . Inhibition of p21-ras activity using either a dominant inhibitory p21-ras mutant or farsenyltransferase inhibitors resulted in reduced astrocytoma cell proliferation in vitro and tumor growth in vivo.
In addition to the p21-ras signaling pathway, activation of other small GTPase proteins may also result in increased cell proliferation in astrocytomas.
To this end, the TSC2 gene product, tuberin, functions as a negative regulator of rap1. Loss of tuberin expression has recently been demonstrated by our laboratory in one third of sporadic gliomas, suggesting that alterations in the rap1 signaling pathway may be associated with the development of human astrocytomas (Wienecke et al., in press) . In this study, we test the hypothesis that alterations in the rap1 signaling pathway, either due to rap1 overexpression or reduced levels of the rap1 negative regulator, tuberin, are frequently associated with gliomas compared to other tumors of the nervous system.
Tuberin has been demonstrated to suppress cell growth and this activity resides in the C-terminus of tuberin where the domain that functions as a GTPase activating protein (GAP) for rap1 is located (Jin et al., 1996) . Biochemical studies demonstrated that this GAP activity is speci®c for rap1 and not other related small GTPase proteins, including rap2, H-ras and rho (Wienecke et al., 1995) . Loss of tuberin expression would therefore be predicted to lead to elevated rap1 activity in these tumors. At present, there is no biochemical method available to determine rap1 activity in cells to directly test this hypothesis. In addition to loss of tuberin expression, another mechanism for elevated rap1 signaling might result from increased rap1 expression. To this end, amplification of a segment of chromosome 12q containing the rap1B gene has been detected in many dierent tumor types, including astrocytomas He et al., 1994 He et al., , 1995 Khatib et al., 1993; Reifenberger et al., 1996) . In these tumors, there is ampli®cation of the 12q chromosomal region variably containing the CDK4/SAS, MDM2, GLI, AM2R, GADD153, IFNG and RAP1B genes.
To determine whether alterations in the rap1 signaling pathway are observed in human astrocytomas, Western blot analysis was performed on twenty adult astrocytomas (Figure 1a ). Tumor samples were obtained from patients undergoing surgery in the Division of Neurosurgery at the University of Toronto or Washington University School of Medicine. All tumors were obtained in accordance with the respective institutions' Institutional Review Board Human Studies Protocols and classi®ed according to the World Health Organization (WHO) classi®cation of tumors of the central nervous system. For control purposes, normal cortex tissue was obtained from patients who underwent cerebral resection because of contusion. Mouse neocortical astrocyte cultures were generated as previously described (Hewett et al., 1995) . The tumor samples were coded in order to conduct the experiments in a blind fashion. Brie¯y, specimens were minced and lysed with the use of a Dounce homogenizer in NP40 lysis buer (50 mM Tris, pH 7.4; 150 mM NaCl; 0.5% NP-40, 1 mM DTT) and protease inhibitors while maintained on ice (Wienecke et al., in press ). The protein content was determined using a modi®ed Bradford reagent (BIORAD) and 75 micrograms of each sample was subjected to 18% SDS polyacrylamide gel electrophoresis. The proteins were electroblotted onto Immobilon-P membranes and the blots were incubated with the appropriate primary antibodies and developed with horseradish peroxidase-based enhanced chemiluminescence detection (ECL; Amersham).
Reduced or absent tuberin expression was detected in nine of twenty tumors relative to normal human brain or mouse astrocyte culture controls. For these studies, reduced or absent tuberin expression was de®ned as less than 10% of control tissue (brain or primary cultured mouse neocortical astrocytes) as determined by scanning densitometry. Equal loading was veri®ed using anti-actin polyclonal antibodies (data not shown; see Figure 3b ). Similar analysis of an additional 18 adult astrocytomas demonstrated reduced or absent tuberin expression in ®ve tumors. In total, reduced tuberin expression was observed in a total of 14 of 38 astrocytomas (37%). Increased rap1 expression was observed in ®ve of the 20 astrocytomas shown in Figure  1 . In this study, increased rap1 expression was de®ned as greater than tenfold increased expression over control tissues (brain or primary astrocytes) as determined by scanning densitometry. The ®ve astrocytomas overexpressing rap1 had normal levels of tuberin. Similar analysis of an additional 18 adult astrocytomas demonstrated increased rap1 expression in ®ve tumors, all of which had normal levels of tuberin expression. In total, increased rap1 expression was observed in a total of 10 of 38 astrocytomas (26%). Therefore, 24 of 38 (63%) sporadic astrocytomas demonstrated potential alterations in the rap1 signaling pathway. Consistent with the hypothesis that alterations in the rap1 signaling pathway result from either an increase in rap1 expression or a loss of tuberin expression, we observed overexpression of rap1 only in gliomas that maintained tuberin expression. There were no clinical dierences in terms of age, gender, location of tumor and survival between this cohort of malignant astrocytomas compared to other astrocytomas, or between the group with decreased tuberin expression compared to those overexpressing rap1.
To determine if alterations in rap1 were unique to astrocytomas, we examined ependymomas and oligodendrogliomas (both less prevalent subtypes of human gliomas) as well as other non-glial nervous system tumors. In six spinal ependymomas, tuberin expression was reduced in two tumors, while rap1 expression was increased in an additional tumor, for a total of 50% of the ependymomas demonstrating defects in the rap1 signaling pathway (data not shown). Using rap1A and rap1B speci®c antibodies, the rap1 ampli®cation observed in these tumors was shown to represent increased rap1B expression (Figure 2a ). In this representative Western blot, six meningioma tumors were analysed sequentially using goat polyclonal rap1 isoform-speci®c antibodies. The two tumors with increased rap1 expression (denoted by the asterisks) demonstrated increased rap1B, but not rap1A, expression. This was also con®rmed by Northern blot (317, 352, 5295, 4295, 813, 820, 834, 858 and 859) and increased rap1 expression in an additional ®ve tumors (397, 410, 805, 806 and 827 ). Brain and m.A. correspond to human normal brain and mouse neocortical astrocytes, respectively. Asterisks above the ®gure denote reduced tuberin expression (510% normal brain control) while asterisks below the ®gure denote increased rap1 expression (4tenfold relative to normal brain control). (b) Western blotting of protein lysates from eight sporadic oligodendroglioma tumors with the rabbit polyclonal tuberin C20 antibody (Santa Cruz Biotechnology; 1 : 1000 dilution) and mouse monoclonal rap1 antibody (Transduction Laboratories; 1 : 500 dilution) demonstrated no reduction in tuberin expression or increased rap1 expression. Brain corresponds to human normal brain. Asterisks above the ®gure denote reduced tuberin expression (510% normal brain control) while asterisks below the ®gure denote increased rap1 expression (4tenfold relative to normal brain control). All quantitation was performed by scanning densitometry using NIHImage 1.55 software analysis using a rap1B-speci®c probe in selected sporadic astrocytomas (data not shown). Similar to the sporadic astrocytomas, none of the ependymomas analysed had both reduced tuberin and increased rap1 expression.
To demonstrate that rap1B expression is not restricted to any particular brain region or developmental age, we performed RT ± PCR analysis using rap1B-speci®c primers on selected microdissected regions of adult and neonatal brain (Figure 2b ). Six to 12 individual mice were used for each tissue sample. Extracted RNA was reverse-transcribed using SuperScript II RNA reverse transcriptase and random hexamers at 418C as previously described. Rap1B 5' -CCATCCAACATCTTAAATGGAC -3' and 5'-CAGCTGCAAACTCTAGGACTATT-3') and cyclophilin primers were used to amplify rap1B and cyclophilin cDNA as previously described (Geist et al., 1996) . Similar levels of expression of rap1B were observed in all regions of adult mouse brain examined as well as postnatal day 4 (PN4) and postnatal day 14 (PN14) neonatal mouse brain. Cyclophilin was used as an internal control for RNA quality and quantity.
The second most common human glioma after astrocytoma is the oligodendroglioma. Oligodendrogliomas can occur alone either as a low grade or as a mixture of malignant astrocytes and oligodendrocytes (mixed oligodendroglioma). These tumors can ultimately undergo further malignant transformation to anaplastic oligodendroglioma and ®nally to a tumor similar pathologically and clinically to a GBM. To determine whether alterations in the rap1 signaling pathway are observed in these tumors, eight oligodendrogliomas (®ve pure oligodendrogliomas and three mixed oligodendrogliomas) were examined by Western blotting. None of the eight tumors demonstrated increased expression of rap1 or reduced tuberin expression (Figure 1b) .
To determine whether alterations in the rap1 signaling pathway are a common feature of other non-glial nervous system tumors, similar analyses were performed on meningiomas and schwannomas. These results are shown in Figure 3a and summarized by tumor type in Table 1 . In 15 meningiomas taken from patients who did not meet diagnostic criteria for neuro®bromatosis 2 (NF2) based on detailed history, physical examination and magnetic resonance imaging studies, three tumors demonstrated reduced tuberin expression while two additional tumors had increased rap1 expression. In total, ®ve out of 15 sporadic meningiomas (33%) demonstrated defects in the rap1 signaling pathway. In six sporadic schwannomas from individuals without NF2, only one tumor each demonstrated either reduced tuberin expression or increased rap1 expression (Figure 3b ). One additional schwannoma without increased rap1 or reduced tuberin expression was not included in Figure 3b . In total, two of six (33%) of sporadic schwannomas had alterations in the rap1 signaling pathway. In total, 33% of these non-glial nervous system tumors had alterations in the rap1 signaling pathway, suggesting that defects in this pathway may not be as frequent a feature in the development of these tumors compared to astrocytomas and ependymomas. Additional analyses will be required to con®rm these initial observations.
To better de®ne the increased rap1 expression seen in these tumors, we performed Western blot analysis using antibodies that recognize the locally¯anking CDK4 gene on chromosome 12q13-q15. Previous studies have demonstrated that the increased rap1B mRNA expression noted in some astrocytomas results in part from ampli®cation of a region on chromosome 12q13-q15, containing the MDM2 and CDK4 genes (Reifenberger et al., 1996; Roy et al., 1995) . Western blotting using antibodies speci®c for CDK4 on ®ve astrocytomas demonstrated increased CDK4 protein expression in the same two astrocytomas with increased rap1 expression (Figure 4a ). These results collectively suggest that increased rap1 expression in these tumors results from an ampli®cation of the region on chromosome 12q containing CDK4 and rap1B. RT ± PCR analysis of rap1B expression in selected regions of the brain. RNA was extracted from microdissected regions from six to 12 individual adult and neonatal mouse brains and reversetranscribed prior to PCR using rap1B and cyclophilin primers. Rap1B and cyclophilin primers amplify products of 149 nt and 206 nt, respectively. PCR was accomplished using an annealing temperature of 558C with 25 (cyclophilin) or 30 (rap1B) cycles of ampli®cation. Products were separated by non-denaturing 8% PAGE and visualized by ethidium bromide staining
Since there are two rap1 negative regulators (tuberin and rap1GAP) expressed in astrocytes (Geist et al., 1996; Wienecke et al., 1996 , we tested the hypothesis that reduced or absent rap1GAP expression may be contributing to aberrant rap1 signaling in those tumors lacking rap1B ampli®cation or reduced tuberin expression. As shown in Figure 4b , expression of the other rap1GAP molecule, p55-rap1GAP, was not altered in these tumors, suggesting that loss of rap1GAP expression is not associated with the antibodies demonstrated reduced or absent tuberin expression in three meningioma tumors (527, 401 and 303) and increased rap1 expression in an additional two meningioma tumors (601 and 495). Brain corresponds to human normal brain. Asterisks above the ®gure denote reduced tuberin expression (510% normal brain control) while asterisks below the ®gure denote increased rap1 expression (4tenfold relative to normal brain control). (b) Western blotting with tuberin (C20) and rap1 antibodies demonstrated reduced or absent tuberin expression in schwannoma tumor 557 and increased rap1 expression in schwannoma tumor 474. Brain corresponds to human normal brain. Asterisks above the ®gure denote reduced tuberin expression (510% normal brain control) while asterisks below the ®gure denote increased rap1 expression (4tenfold relative to normal brain control). Actin (rabbit polyclonal antibody; Sigma) was included in this experiment as an internal control for equal protein loading Increased rap1 expression is de®ned as 410-fold rap1 expression relative to normal brain or mouse neocortical astrocytes by Western blot as determined by scanning densitometry using NIH-Image 1.55 progression to malignancy in these tumors. An analogous observation with the two main mammalian p21-ras-GAPs, p120-GAP and neuro®bromin (neuro®bromatosis 1 gene product), has been made. In these studies, neuro®bromin expression was reduced or absent in several dierent tumor types, but no changes in p120-GAP expression were observed (Johnson et al., 1993; The et al., 1993) .
Previous work from our laboratory has demonstrated increased p21-ras activity in sporadic astrocytomas (Guha et al., manuscript submitted; Gutmann et al., 1996) , although unlike 30 ± 40% of all human cancers, nervous system tumors do not harbor oncogenic ras mutations. We postulate that the increased p21-ras activity in astrocytomas arise from upstream signals transmitted via the p21-ras pathway from receptor tyrosine kinases such as epidermal growth factor receptor and platelet derived growth factor receptor, which are overexpressed in these tumors (Guha et al., manuscript submitted; Gutmann et al., 1996) . The results described in this report taken together with the previous work on astrocytomas, argue that alterations in signaling pathways mediated by small G-proteins, such as p21-ras and rap1, are frequent occurrences in certain subsets of glioma, such as astrocytoma and ependymoma.
Aberrations in tuberin, p55 rap1GAP and rap1 expression were not found in oligodendrogliomas, the second most common subtype of human gliomas after astrocytomas. This was irrespective of whether they were composed of only malignant oligodendrocytes or were a mixed oligodendroglioma. Molecular genetic alterations associated with early stages of pure and mixed oligodendrogliomas are thought to dier from astrocytomas, involving loss of putative tumor suppressor genes on chromosomes 1p and 19q (Kraus et al., 1995) . Loss of heterozygosity on chromosome 16p (site of TSC2), ampli®cation of 12q (site of RAP1B) and mutations in the p53 gene are not associated with the early molecular pathogenesis of oligodendrogliomas, unlike their association with the development of astrocytomas. However, transformation of lower grade oligodendroglial tumors to anaplastic oligodendrogliomas and ultimately to a tumor pathologically similar to a GBM, are associated with molecular events common to human malignant astrocytomas, involving loss of putative tumor suppressor genes on chromosome 10 and ampli®cation of EGF-R (Reifenberger et al., 1994; Louis and Gusella, 1995) .
The role of rap1 signaling in astrocyte cellular function and transformation is not known. Under some circumstances, rap1 antagonizes p21-ras activity and inhibits p21-ras transformation in ®broblasts. In other studies, rap1 has been demonstrated to induce ®broblast proliferation (Yoshida et al., 1992 ). Our results demonstrate that a signi®cant percentage of gliomas may have aberrant rap1 signaling, either due to reduced negative regulation by tuberin or increased rap1 expression secondary to chromosomal amplification. Furthermore, the protein analysis may actually underestimate the frequency of rap1 pathway alterations since activating mutations of rap1B as well as tuberin missense mutations would not be detected. The fact that we have observed reduced tuberin expression or increased rap1 expression in dierent tumor specimens of the same type suggests a potentially antagonistic relationship between the products of the RAP1 genes and the TSC2 gene. This type of relationship seems consistent with tuberin acting as a negative regulator of rap1 in a cellular signaling pathway, although we cannot exclude other scenarios. In this regard, the direct measurement of rap1 activity in glioma cell cultures or specimens would provide direct proof that aberrant rap1 activity was present in human gliomas. Presently this is not feasible due to lack of an antibody able to lock rap1 into its GDPbound or GTP-bound conformation, as does the antiras Y13-259 antibody. However, the ability of rap1 to activate directly B-raf (Ohtsuka et al., 1996) , combined with our results demonstrating the importance of the p21-ras/raf/MAP kinase signaling pathway in astrocytomas, suggests that the eects of these two small Gproteins may converge downstream to provide a growth promoting signal for gliomas. Further understanding of the roles and interactions of these two Gprotein mediated signaling pathways in the pathogenesis of gliomas may result in novel targeted biological therapies. 
